Phase 3 RCT in 667 men with BPH (619 analysed): dutasteride/tadalafil combination improved IPSS more than dutasteride (LSMD -5.09) or tadalafil alone (LSMD -5.29) at 48 weeks, with more adverse events (32.88% vs 21.20% and 26.48%).
RCTn = 667 patients
Lee et al. Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial